All In Biotech

Drug Trial Radar · NCT00036543

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Aug 15, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,000

Actual

Start

May 2001

Primary completion

Not stated

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
May 13, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Male only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • AtrasentanDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary objective of this study is to evaluate safety and efficacy as measured by time-to-disease progression

Locations

232 sites in 18 countries. Site status is shown where the registry gives one.

  • Urology Centers Of Alabama

    Homewood, Alabama

  • Alaska Clinical Research Center, LLC

    Anchorage, Alaska

  • Advanced Clinical Trials

    Tucson, Arizona

  • Arkansas Urologial Associates, PA

    Little Rock, Arkansas

  • Robin V. Smith, MD

    Chula Vista, California

  • Urology Associate Of Central California

    Fresno, California

  • South Valley Medical Plaza

    Gilroy, California

  • San Diego Urology Center

    La Mesa, California

  • UCLA School Of Medicine

    Los Angeles, California

  • Hillcrest Urological Medical Group, Inc.

    San Diego, California

  • Urology Associates Of San Luis Obispo

    San Luis Obispo, California

  • Pacific Clinical Research

    Santa Monica, California

  • Western Clinical Research, Inc.

    Torrance, California

  • Urology Associate, Pc

    Denver, Colorado

  • South Fl Medical Research

    Aventura, Florida

  • Clinical Physiology Associates

    Fort Myers, Florida

  • Advanced Research Institute

    New Port Richey, Florida

  • Urology Treatment Center

    Sarasota, Florida

  • Southeastern Urological Center, P.A.

    Tallahassee, Florida

  • Winship Cancer Institute Emory University

    Atlanta, Georgia

  • Sandy Springs Urology

    Atlanta, Georgia

  • Atlanta Va Medical Center

    Decatur, Georgia

  • Dreyer Medical Clinic

    Aurora, Illinois

  • Progressive Care, S.C.

    Chicago, Illinois

  • Weiss Memorial Hospital

    Chicago, Illinois

  • Evanston Hospital Kellogg Cancer Center

    Evanston, Illinois

  • Welborn Clinic

    Evansville, Indiana

  • Urologic Associates, Pc

    Davenport, Iowa

  • Iowa Urology

    Des Moines, Iowa

  • Kansas University Medical Center

    Kansas City, Kansas

  • Ochsner Clinic, Department of Urology

    New Orleans, Louisiana

  • Regional Urology

    Shreveport, Louisiana

  • LSUHSC

    Shreveport, Louisiana

  • Johns Hopkins Oncology Center

    Baltimore, Maryland

  • Mid Atlantic Clinical Research

    Rockville, Maryland

  • Michigan Institute Of Urology, Pc

    Saint Clair Shores, Michigan

  • Lakeside Urology, PC

    Saint Joseph, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • The Medical Oncology Group

    Gulfport, Mississippi

  • St. Joseph Oncology

    Saint Joseph, Missouri

Showing 40 of 232 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.